Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akihisa Nagata

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Oncogene|March 16, 2002
Cdc6 requires anchorage for its expressionShigeki Jinno, Mika Yageta, Akihisa Nagata, et al.
International Journal of Hematology|January 29, 2015
Significance of lymphocyte counts at diagnosis in the management of ITP: the relationship between lymphocyte counts and treatment success in H. pylori-infected patientsAkihisa Nagata, Naohiro Sekiguchi, Miwa Kurimoto, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 5, 2016
[Achievement of deep molecular response in an elderly chronic myeloid leukemia patient intolerant to imatinib and nilotinib]Miwa Kurimoto, Akihisa Nagata, Naohiro Sekiguchi, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 16, 2011
[Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl]Naohiro Sekiguchi, Naoki Takezako, Mitsuhiro Haga, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|January 16, 2014
Bortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: a pilot studyNaoki Takezako, Naohiro Sekiguchi, Akihisa Nagata, et al.
Internal Medicine (Tokyo, Japan)|November 2, 2011
Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapyNaohiro Sekiguchi, Naoki Takezako, Akihisa Nagata, et al.
International Journal of Hematology|February 6, 2014
Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapyNaohiro Sekiguchi, Kaori Ootsubo, Miyuki Wagatsuma, et al.
Cellular & Molecular Immunology|August 28, 2012
Soluble ST2 protein inhibits LPS stimulation on monocyte-derived dendritic cellsAkihisa Nagata, Naoki Takezako, Hiroyuki Tamemoto, et al.
Thrombosis Research|May 3, 2015
Recombinant human thrombomodulin in the treatment of acute myeloid leukemia patients complicated by disseminated intravascular coagulation: retrospective analysis of outcomes between patients treated with heparin and recombinant human thrombomodulin therapyNaoki Takezako, Naohiro Sekiguchi, Akihisa Nagata, et al.
Biomed Research International|November 8, 2018
Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q DeletionNaohiro Sekiguchi, Junko Nomoto, Akihisa Nagata, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Oncogene|March 16, 2002
Cdc6 requires anchorage for its expressionShigeki Jinno, Mika Yageta, Akihisa Nagata, et al.
International Journal of Hematology|January 29, 2015
Significance of lymphocyte counts at diagnosis in the management of ITP: the relationship between lymphocyte counts and treatment success in H. pylori-infected patientsAkihisa Nagata, Naohiro Sekiguchi, Miwa Kurimoto, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 5, 2016
[Achievement of deep molecular response in an elderly chronic myeloid leukemia patient intolerant to imatinib and nilotinib]Miwa Kurimoto, Akihisa Nagata, Naohiro Sekiguchi, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 16, 2011
[Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl]Naohiro Sekiguchi, Naoki Takezako, Mitsuhiro Haga, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|January 16, 2014
Bortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: a pilot studyNaoki Takezako, Naohiro Sekiguchi, Akihisa Nagata, et al.
Internal Medicine (Tokyo, Japan)|November 2, 2011
Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapyNaohiro Sekiguchi, Naoki Takezako, Akihisa Nagata, et al.
International Journal of Hematology|February 6, 2014
Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapyNaohiro Sekiguchi, Kaori Ootsubo, Miyuki Wagatsuma, et al.
Cellular & Molecular Immunology|August 28, 2012
Soluble ST2 protein inhibits LPS stimulation on monocyte-derived dendritic cellsAkihisa Nagata, Naoki Takezako, Hiroyuki Tamemoto, et al.
Thrombosis Research|May 3, 2015
Recombinant human thrombomodulin in the treatment of acute myeloid leukemia patients complicated by disseminated intravascular coagulation: retrospective analysis of outcomes between patients treated with heparin and recombinant human thrombomodulin therapyNaoki Takezako, Naohiro Sekiguchi, Akihisa Nagata, et al.
Biomed Research International|November 8, 2018
Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q DeletionNaohiro Sekiguchi, Junko Nomoto, Akihisa Nagata, et al.
Pageof 2